arrow
A

Anoop Enjeti

calvary mater hospital
H指数:27
被引数:2,752

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS

TP53突变在高风险骨髓增生异常综合征(MDS)患者接受去甲基化药物治疗后的影响:来自国际MDS联盟VALIDATE数据库的分析

2026-11-140
OAAI
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

基于低甲基化制剂治疗的反应对高风险骨髓增生异常综合征/肿瘤患者生存结局的影响:考虑基线临床-分子风险和移植状态的国际骨髓增生异常综合征联盟(icMDS)分析

2026-08-280
PRE
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

高风险骨髓增生异常综合征/新生物患者接受去甲基化药物+维奈克拉治疗后的结局分析——国际骨髓增生异常综合征(icMDS)VALIDATE数据库分析

2026-06-290
OAAI
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

低剂量阿糖胞苷和维奈克拉在不符合强化疗条件的急性髓系白血病患者中的风险分层

2025-11-240
OAAI
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal

去甲基化药物诱导表观遗传和转录异质性,这对急性髓系白血病细胞的自我更新具有影响。

Leukemia
IF13.4
2025-07-170
OA
A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax plus /- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

一项比较低剂量阿糖胞苷和维奈克拉联合/不联合米哚妥林治疗非不良染色体风险急性髓系白血病的II期随机试验:ALLG AMLM25干预试验

BLOOD
IF23.1
2024-11-050
PRE
Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

使用口服Wnt/β-Catenin通路抑制剂ES-3000联合口服地西他滨/西达佐米定(ASTX727)靶向骨髓增生异常综合征(MDS)炎症小体:一项澳大拉西亚白血病和淋巴瘤小组试验(ALLG MDS05/D1)

BLOOD
IF23.1
2024-11-050
PRE
Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study

Ibrutinib加利妥昔单抗和mini-CHOP治疗新诊断DLBCL的老年患者: 一项2期ALLG研究

2024-11-010
PRE
How comparable are patient outcomes in the real-world with populations studied in pivotal AML trials?
2024-03-260
OAAI
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies
2023-03-2811
PRE